GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Cyclically Adjusted FCF per Share

AIM ImmunoTech (STU:HXB2) Cyclically Adjusted FCF per Share : €-13.55 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AIM ImmunoTech's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-0.091. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-13.55 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AIM ImmunoTech was 22.00% per year. The lowest was 2.60% per year. And the median was 8.80% per year.

As of today (2024-05-24), AIM ImmunoTech's current stock price is €0.354. AIM ImmunoTech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-13.55. AIM ImmunoTech's Cyclically Adjusted Price-to-FCF of today is .


AIM ImmunoTech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for AIM ImmunoTech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cyclically Adjusted FCF per Share Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.67 -28.14 -26.89 -20.20 -15.03

AIM ImmunoTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.15 -16.42 -15.95 -15.03 -13.55

Competitive Comparison of AIM ImmunoTech's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted Price-to-FCF falls into.



AIM ImmunoTech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AIM ImmunoTech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.091/131.7762*131.7762
=-0.091

Current CPI (Mar. 2024) = 131.7762.

AIM ImmunoTech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -7.438 100.560 -9.747
201409 -8.410 100.428 -11.035
201412 -9.034 99.070 -12.016
201503 -10.148 99.621 -13.424
201506 -10.358 100.684 -13.557
201509 -6.690 100.392 -8.781
201512 -6.635 99.792 -8.762
201603 -2.117 100.470 -2.777
201606 -2.943 101.688 -3.814
201609 -5.500 101.861 -7.115
201612 -3.657 101.863 -4.731
201703 -4.880 102.862 -6.252
201706 -3.312 103.349 -4.223
201709 -2.354 104.136 -2.979
201712 -0.901 104.011 -1.142
201803 -2.516 105.290 -3.149
201806 -2.316 106.317 -2.871
201809 -2.425 106.507 -3.000
201812 -1.939 105.998 -2.411
201903 -1.220 107.251 -1.499
201906 -1.345 108.070 -1.640
201909 -0.895 108.329 -1.089
201912 -0.207 108.420 -0.252
202003 -0.174 108.902 -0.211
202006 -0.043 108.767 -0.052
202009 -0.065 109.815 -0.078
202012 -0.063 109.897 -0.076
202103 -0.063 111.754 -0.074
202106 -0.030 114.631 -0.034
202109 -0.063 115.734 -0.072
202112 -0.109 117.630 -0.122
202203 -0.053 121.301 -0.058
202206 -0.046 125.017 -0.048
202209 -0.105 125.227 -0.110
202212 -0.123 125.222 -0.129
202303 -0.071 127.348 -0.073
202306 -0.041 128.729 -0.042
202309 -0.109 129.860 -0.111
202312 -0.183 129.419 -0.186
202403 -0.091 131.776 -0.091

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


AIM ImmunoTech  (STU:HXB2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AIM ImmunoTech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Industry
Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines